New developments with bortezomib in treating multiple myeloma

Clinical Lymphoma

Volumn 4, Issue 4, 2004, Pages 215-216

  Reddy, G Kesava ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CREATININE; DOXORUBICIN; LIPOSOME; PROTEASOME;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; ARTICLE; BODY WEIGHT DISORDER; CANCER SURVIVAL; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY FAILURE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; SCID MOUSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 1942531995     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70035-5     Document Type: Article

References (7)

1. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
2. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
4. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 2003; 102(suppl):449a (Abstract #1639).
5. Lonial S, Waller EK, Richardson P, et al. Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma. Blood 2003; 102(suppl):447a (Abstract #1632).
6. Richardson RG, Briemberg H, Jagannath S, et al. Peripheral neuropathy following bortezomib (VELCADE, formerly PS-341) therapy in patients with advanced multiple myeloma. Blood 2003; 102(suppl): 149a (Abstract #512).
7. Jagannath S, Barlogie B, Berenson J, et al. Limited experience from 2 phase 2 trials suggests bortezomib can be given safely in multiple myeloma (MM) patients (pts) with severe renal impairment with comparable responses and toxicities. Blood 2002; 102(suppl):236a (Abstract #828).